| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
18,540,000 |
| Market
Cap: |
129.04(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.75 - $18.4 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 13.6 |
| Insider 6 Months : 13.6 |
| Insider 3/6 Months : 27.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Co.'s proprietary platform technology, BAROSTIM®, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System (ANS) which causes heart failure (HF) and other cardiovascular diseases. Co.'s second-generation product, BAROSTIM NEO®, is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with HF and resistant hypertension.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
205,429 |
205,429 |
243,929 |
243,929 |
| Total Buy Value |
$1,069,117 |
$1,069,117 |
$1,391,625 |
$1,391,625 |
| Total People Bought |
3 |
3 |
4 |
4 |
| Total Buy Transactions |
7 |
7 |
11 |
11 |
| Total Shares Sold |
0 |
0 |
1,430 |
9,450 |
| Total Sell Value |
$0 |
$0 |
$19,417 |
$202,588 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
5 |
| End Date |
2025-04-10 |
2025-01-07 |
2024-07-09 |
2023-07-10 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nielsen Kirk G. |
|
– • – |
2025-05-15 |
4 |
B |
$5.45 |
$59,795 |
I/I |
10,966 |
1,910,134 |
0.01 |
9% |
|
| Nielsen Kirk G. |
|
– • – |
2025-05-14 |
4 |
B |
$5.23 |
$320,364 |
I/I |
61,200 |
1,899,168 |
0.01 |
28% |
|
| Jain Mudit K. |
|
– • – |
2025-05-13 |
4 |
B |
$5.26 |
$789 |
D/D |
150 |
5,050 |
0.01 |
24% |
|
| Nielsen Kirk G. |
|
– • – |
2025-05-13 |
4 |
B |
$5.29 |
$536,313 |
I/I |
101,413 |
1,837,968 |
0.01 |
24% |
|
| Jain Mudit K. |
|
– • – |
2025-05-12 |
4 |
B |
$4.66 |
$6,986 |
D/D |
1,500 |
4,900 |
0.01 |
42% |
|
| Nielsen Kirk G. |
|
– • – |
2025-05-12 |
4 |
B |
$4.79 |
$120,670 |
I/I |
25,200 |
1,736,555 |
0.01 |
42% |
|
| Hykes Kevin |
PRES & CEO |
• • – |
2025-05-12 |
4 |
B |
$4.84 |
$24,200 |
D/D |
5,000 |
133,000 |
0.01 |
42% |
|
| John Robert Allen |
Chief Revenue Officer |
• – – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
55,000 |
55,000 |
|
- |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
16,835 |
|
- |
|
| Hykes Kevin |
PRES & CEO |
• • – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
98,000 |
128,000 |
|
- |
|
| Oasheim Jared |
CHIEF FINANCIAL OFFICER |
• – – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
22,000 |
37,447 |
|
- |
|
| Adamson Philip B. |
Chief Medical Officer |
• – – |
2025-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2024-11-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,040 |
835 |
|
- |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2024-11-19 |
4 |
S |
$13.58 |
$19,417 |
D/D |
(1,430) |
1,875 |
|
3% |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2024-11-19 |
4 |
OE |
$5.14 |
$12,853 |
D/D |
2,500 |
3,305 |
|
- |
|
| Slattery Joseph P |
|
– • – |
2024-08-15 |
4 |
B |
$8.10 |
$24,300 |
D/D |
3,000 |
30,645 |
0.01 |
56% |
|
| Slattery Joseph P |
|
– • – |
2024-08-08 |
4 |
B |
$8.24 |
$24,716 |
D/D |
3,000 |
27,645 |
0.01 |
55% |
|
| Slattery Joseph P |
|
– • – |
2024-08-06 |
4 |
B |
$9.09 |
$22,725 |
D/D |
2,500 |
24,645 |
0.01 |
42% |
|
| Hykes Kevin |
PRES & CEO |
• • – |
2024-08-05 |
4 |
B |
$8.36 |
$250,767 |
D/D |
30,000 |
30,000 |
0.01 |
58% |
|
| Palmer Craig E. |
SVP, U.S. SALES |
• – – |
2024-03-25 |
4 |
OE |
$0.24 |
$221 |
D/D |
934 |
1,229 |
|
- |
|
| Johnson & Johnson Development Corp Et Al |
|
– – • |
2024-02-29 |
4 |
OE |
$0.24 |
$2,792 |
I/I |
3,855 |
4,103,430 |
|
- |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2024-02-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,650 |
805 |
|
- |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2024-02-20 |
4 |
S |
$21.91 |
$55,748 |
D/D |
(2,545) |
2,455 |
|
47% |
|
| Verrastro Paul |
CHIEF MKTG & STRAT OFFICER |
• – – |
2024-02-20 |
4 |
OE |
$5.14 |
$25,705 |
D/D |
5,000 |
5,000 |
|
- |
|
| Johnson & Johnson Development Corp Et Al |
|
– – • |
2024-02-16 |
4 |
S |
$25.81 |
$96,142 |
I/I |
(3,725) |
4,099,575 |
|
47% |
|
85 Records found
|
|
Page 1 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.21 (3.11%) 
